Celsion (CLSN) issues a statement in response to yesterday's Seeking Alpha blog, calling it misleading and requiring clarification. The company says it's conducted extensive post hoc analysis of the data from the ThermoDox studies with its key experts, and found that its use in conjunction with RFA to treat hepatocellular carcinoma suggests it markedly improves survival if the lesions undergo RFA for 45 minutes or more. While the study hasn't yet reached its median survival endpoint, the data shows a strong signal which its experts consider to be encouraging enough to warrant further clinical investigation.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs